Navigation Links
Global Stem Cells Group Named Authorized Distributor of GMTN Exosome Injection and Other Biological Products
Date:2/11/2016

Global Stem Cells Group, a world leader in regenerative medicine, has announced a new agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) to distribute exosome injection and other biological products to stem cell researchers and phsyicians in 15 Latin American countries, including Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, Nicaragua, Panama, El Salvador, Venezuela, Peru, Ecuador, Paraguay, Puerto Rico, Chile Bolivia and Uruguay.

The agreement gives Global Stem Cells Group exclusive distribution rights for the following GSCN products:

  • Exosome Injection, a human induced pluripotent stem cell-derived mesenchymal stem cell treatment, which has emerged as a promising supplement to stem cell transplantation therapies. Exosomes derived from mesenchymal stem cells can play an important role in repairing injured tissues. Exosome injection is also utilized as a complement to bone marrow stem cell extractions.
  • GcMaf ( Goleic) Injections, a breakthrough technology used to counteract the effects of immune system suppression caused by cancerous tumor cells. Complementary oncology utilizes GcMAF therapy to boost the patient’s immune system. Peer reviewed studies have proven that GcMAF Goleic therapy is an immune activator, and can be used as a natural cancer treatment. GcMAF Goleic inhibits blood supply to tumors, activates self-destruction of cancer cells, reverts cancer cells’ characteristics to normal healthy cells, reduces the metastatic potential of human cancer cells and increases energy production at the mitochondrial level.
  • Myopep Injection provides a potentially integral part of muscular enhancement and sports medicine rehabilitation, as well as therapeutic care for type 2 diabetes-related weight issues, obesity-related weight loss, aging-related muscle wasting and cerebral palsy. Myopep utilizes bio-engineered peptides to effectively inhibit myostatin, the growth and differentiation factor found in muscle receptor sites. Successful clinical trials demonstrate significant fat loss and muscle gain. Myopep is capable of inducing a pharmaceutical grade effect in human muscle and adipose fat function. Metabolism or glycolysis (sugar metabolism) rises, forcing fat to be broken down into sugar to feed muscular action and growth, causing increased muscle growth, definition and strength. One subcutaneous injection of Myopep at the abdominal area weekly over a period of two months has shown significant fat loss in clinical trials, and a significant drop in glucose metabolic parameters.

“Global Stem Cells Group strives to remain in the forefront of non-invasive, natural medical therapies that provide options for patients who are not finding relief through traditional treatments, and GSCN’s biological products are valuable in achieving these goals,” says Global Stem Cells Group CEO Benito Novas. “As the exclusive distributor of GSNC products in Latin America, this is an excellent opportunity to offer patients access to the most cutting-edge natural remedies available.”

For more information, visit the Global Stem Cells Group website, email info(at)stemcelltraining(dot)net, or call (305) 560-5337.

About Global Stem Cell Group:

Global Stem Cells Group is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

About Global Stem Cells Network (GSCN):

Bangkok, Thailand-based Global Stem Cells Network is made up of internationally-trained physicians and health care professionals dedicated to providing the safest, most effective stem cell treatments available today. GSCN is a recognized and trusted leader in providing stem cell specialist treatment programs since 2010, and related medical care since 2003.

###

Read the full story at http://www.prweb.com/releases/GlobalStemCellsGroup/GSNCBiologicProducts/prweb13210198.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related biology technology :

1. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
2. Guidepoint Global Launches Two Major Enhancements to its Client Research Portal
3. Global Regulatory Milestones for Invibio Biomaterial Solutions
4. DuPont Joins Israel’s Office of the Chief Scientist Global Enterprise R&D Cooperation Framework
5. Global Metabolomics (Biomarker Discovery/Metabolite Detection/Metabolite Profiling) - 2013 Market Report
6. Lucintel's Analysis of Global Catalysts Industry: Chemical and Automobile Industries Play Crucial Role in Growth
7. Global Biochips and Microarrays 2013 Market Report
8. Global Bio-implants Market 2012-2016 New Research Report Now Available at MarketResearchReports.biz
9. USP Global Fellowship Awards Program Call for Applications
10. Medical Gases and Equipment Market is Expected to Reach USD 9 Billion Globally in 2018: Transparency Market Research
11. Global Food Safety Testing Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/13/2018)... ... ... Asymmetrex’s director, James L. Sherley, M.D., Ph.D., asks audiences questions like, “How ... the means to measure the number of drug molecules in drug development research or ... holding up progress in stem cell medicine.” , “Can you imagine taking an approved ...
(Date:9/12/2018)... ... September 11, 2018 , ... Leading regenerative ... of Feline Practitioners Conference (AAFP) later this month. The company’s CEO ... therapy for the treatment of chronic kidney disease in felines at a poster ...
(Date:9/12/2018)... (PRWEB) , ... September 12, 2018 , ... ... Bronich-Hall, a quality management professional and former Senior Director of Regulatory Affairs and ... , As Senior Director of Regulatory Affairs and Quality Systems at WellDoc, ...
(Date:9/7/2018)... ... 06, 2018 , ... The Discovery on Target (DOT) conference ... industry’s preeminent event on novel drug targets.” BellBrook Labs’ high throughput screening (HTS) ... emerging targets in a quest to find new treatments for disease. , BellBrook ...
Breaking Biology Technology:
(Date:8/23/2018)... (PRWEB) , ... August 22, 2018 , ... ... release of LimitLIS® 4.0, the latest version of its rapidly growing cloud-based laboratory ... LimitLIS® Toxicology Edition, as well as the company’s triple digit growth throughout 2018, ...
(Date:8/21/2018)... ... August 20, 2018 , ... ... are many challenges to consider. Designers must ensure what is designed can be ... will explore some best practices in flow path design with specific focus on ...
(Date:8/21/2018)... ... August 21, 2018 , ... Whether it ... Labs is dedicated to offering customers a successful experience. When browsing the ... seamless transition between products, with relevant details such as technical manuals, application notes, ...
Breaking Biology News(10 mins):